Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-20-012099
Filing Date
2020-08-07
Accepted
2020-08-07 08:50:38
Documents
86
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q mrsn-20200630.htm   iXBRL 10-Q 1600300
2 EX-10.1 exhibit10110-qfy2020q2.htm EX-10.1 620911
3 EX-31.1 exhibit31110-qfy2020q2.htm EX-31.1 11810
4 EX-31.2 exhibit31210-qfy2020q2.htm EX-31.2 11759
5 EX-32.1 exhibit32110-qfy2020q2.htm EX-32.1 7542
11 image011.jpg GRAPHIC 1766480
12 image111.jpg GRAPHIC 1485937
  Complete submission text file 0001628280-20-012099.txt   12542366

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrsn-20200630.xsd EX-101.SCH 52124
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrsn-20200630_cal.xml EX-101.CAL 83574
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrsn-20200630_def.xml EX-101.DEF 256452
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrsn-20200630_lab.xml EX-101.LAB 585240
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrsn-20200630_pre.xml EX-101.PRE 410171
13 EXTRACTED XBRL INSTANCE DOCUMENT mrsn-20200630_htm.xml XML 1306583
Mailing Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 617-498-0020
Mersana Therapeutics, Inc. (Filer) CIK: 0001442836 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38129 | Film No.: 201083909
SIC: 2834 Pharmaceutical Preparations